RXi Pharmaceuticals Initiates Phase 1/2 Trial For Scarring Of Wet-Age Related Macular Degeneration
November 05, 2015 at 16:11 PM EST
RXi Pharmaceuticals announced that it has initiated its Phase 1/2 trial for retinal scarring of Wet-Age related macular degeneration -- Wet AMD.